Search articles in News
Filter Articles
Found 1,971 articles
AION Labs, In Continued Partnership with BioMed X, Launches New Global Call for Applications: Identification of Active Small Molecules for Drug Discovery
- 25 May 2023
AION Labs, a first-of-its-kind innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, and German independent research institute BioMed X, announced today the launch of its latest global call for applications to identify AI and machine learning professionals and biomedical scientists and inventors to form a new startup at AION Labs’ headquarters in Rehovot, Israel.
Kristin Judge Joins Emmes as Chief Growth Officer
- 25 May 2023
Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that Kristin Judge has joined as its chief growth officer, a newly created executive leadership position.
Susan Rienow becomes President of the ABPI
- 24 May 2023
Susan Rienow, UK Managing Director and Country President of Pfizer, is taking up her role as President of the Association of the British Pharmaceutical Industry. She will lead on overseeing the ABPI, the ABPI Board, and the ABPI’s Code of Practice, which is administered by the Prescription Medicines Code of Practice Authority (PMCPA).
Fixed Phage accelerates growth strategy with appointment of new CEO and top team
- 24 May 2023
Innovative UK phage biotechnology company, Fixed Phage, has appointed Dr Neil Clelland as its new Chief Executive Officer (CEO). The company has also announced its new Chief Operations Officer (COO) and Executive Chairman. These appointments strengthen the top management team, leading the company as it drives forward its new phase of growth and development.
Board Appointment
- 24 May 2023
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, announces the appointment of Brendan Buckley as an Independent Non-Executive Director of the Company with immediate effect. Brendan will also replace Cathal Friel as a member of the Remuneration Committee.
-
New senior hire for medical writing team at Boyds
- 24 May 2023
Leading global drug development consultancy Boyds has made a new appointment to its medical writing team in response to rising demand for its services. Naomi Clout joins the Boyds team as Senior Regulatory and Medical Writer, after working with the company on a consultancy basis for a number of years.
Copley’s appointment of new Applications Specialist, Clair Brooks, highlights commitment to exemplary customer support
- 23 May 2023
Copley Scientific, a major provider of pharmaceutical testing systems with world-renowned expertise in the field of orally inhaled and nasal drug products (OINDPs), has appointed a new Applications Specialist to maintain a customer-centric focus as growth continues.
ONA Therapeutics Announces the Appointment of Dr Pamela Klein to its Board of Directors
- 23 May 2023
ONA Therapeutics (“ONA”), which is specialized in unravelling novel biology to design biopharmaceuticals attacking advanced cancer, is pleased to announce the appointment of Dr. Pamela Klein as independent member to its board of directors.
Engimmune Therapeutics Announces the Appointment of Dr Annalisa D’Andrea to its Board of Directors
- 23 May 2023
Engimmune Therapeutics AG (“Engimmune”), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, is pleased to announce the appointment of Dr Annalisa D’Andrea to its board of directors as a non-executive director as of the 1 of June 2023.
BIAL Appoints Melanie Lee As Non-Executive Board Member
- 23 May 2023
BIAL, an innovation-driven pharmaceutical company aiming to improve people’s lives worldwide, has announced the appointment of Melanie Lee as a non-executive member of its Board of Directors.
Jessamy Baird of Sanofi named as new ABPI Vice-President Elect
- 18 May 2023
Jessamy will join and support ABPI President Elect Susan Rienow, UK Managing Director and Country President of Pfizer, in delivering her presidential priorities and support the ABPI in its mission to make the UK the best place in the world to research, develop and use the medicines and vaccines of the future. Both Jessamy and Susan will formally take up their new roles on Wednesday 25 May.
Inizio Targets Innovation and AI-Led Growth with Two Top Appointments
- 18 May 2023
Inizio, a partner for health and life sciences that seamlessly connects best-in-class strategic, analytic and creative capabilities has strengthened its senior leadership team at Inizio Medical with the dual appointments of Matt Lewis as Global Chief Artificial and Augmented Intelligence Officer and Paul Hatton as President, Medical Analytics and Innovation, in response to seismic technology trends reshaping the industry.
Terumo Blood and Cell Technologies appoints Veerle d’Haenens as General Manager, Cell Therapy Technologies
- 18 May 2023
Terumo Blood and Cell Technologies, a medical technology company, today announced the promotion of Veerle d’Haenens to General Manager, of Global Therapeutic Systems and Cell Therapy Technologies businesses, expanding her role to include growing the company’s cell therapy manufacturing solutions.
LEON appoints Dr. Setu Kasera as Chief Scientific Officer
- 16 May 2023
leon-nanodrugs GmbH (“LEON”), a disrupting enabler of nanotechnology for the pharmaceutical industry, today announced the appointment of Dr. Setu Kasera as Chief Scientific Officer, effective May 15, 2023. Since October 2022, Dr. Kasera has been driving the development of LEON’s devices as Head of Science and Engineering to put the proprietary technology to practice, while the Company has increased the pace of product development to get it across the finishing line.
Accumulus Synergy Announces the Appointment of New Leadership Team Members
- 16 May 2023
Accumulus Synergy (“Accumulus”), a nonprofit trade association working to address the global need for digital transformation within the life sciences - health authority ecosystem, today announced the appointment of two new executive members of the trade association’s leadership team.
HUTCHMED Announces Board of Directors and Board Committee
- 12 May 2023
HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) refers to its announcement on May 10, 2023 of the appointment of Professor Solange Peters as an Independent Non-executive Director, member of the Technical Committee and member of the Audit Committee of the Company with effect from the conclusion of the annual general meeting of the Company to be held on May 12, 2023 (“AGM”).
Vicore Strengthens its Board Of Directors
- 12 May 2023
Vicore Pharma Holding AB (STO: VICO) (“Vicore”), unlocking the potential of a new class of drugs – angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the Annual General Meeting’s election of two very experienced board members, Dr Elisabeth Björk and Dr Michael Buschle.
ELRIG UK Appoints Nick Clare to Board as Vendor Strategy Work Group Lead
- 12 May 2023
The European Laboratory Research & Innovation Group (ELRIG) UK today announced the appointment of Nick Clare to the ELRIG board. He will chair and lead the Vendor Strategy Work Group to help ensure the vendors’ perspectives and interests are represented within the ELRIG board.
Impact Shine Communications rolls in to advance Life Science Business and Marketing Strategies
- 11 May 2023
Impact Shine Communications – the strategic life science communications and public affairs agency – is pleased to announce the launch of its new website highlighting its full suite of services for the industry and market.
Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy
- 11 May 2023
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the first participant in Australia has been treated in the Company’s Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder.
